What is HC Wainwright’s Forecast for RARE Q1 Earnings?

Ultragenyx Pharmaceutical Inc. (NASDAQ:RARE) – Research analysts at HC Wainwright issued their Q1 2025 earnings estimates for Ultragenyx Pharmaceutical in a report issued on Wednesday, November 6th. HC Wainwright analyst E. Arce expects that the biopharmaceutical company will post earnings per share of ($1.20) for the quarter. HC Wainwright has a “Buy” rating and a $95.00 price objective on the stock. The consensus estimate for Ultragenyx Pharmaceutical’s current full-year earnings is ($6.29) per share. HC Wainwright also issued estimates for Ultragenyx Pharmaceutical’s Q4 2025 earnings at ($0.96) EPS.

Several other equities analysts also recently issued reports on the stock. Cantor Fitzgerald reissued an “overweight” rating and set a $116.00 price target on shares of Ultragenyx Pharmaceutical in a report on Wednesday. Barclays cut their target price on shares of Ultragenyx Pharmaceutical from $83.00 to $81.00 and set an “overweight” rating for the company in a research note on Monday, August 5th. Royal Bank of Canada restated an “outperform” rating and set a $77.00 price target on shares of Ultragenyx Pharmaceutical in a research report on Wednesday. TD Cowen lifted their price objective on Ultragenyx Pharmaceutical from $61.00 to $73.00 and gave the company a “buy” rating in a research report on Monday, October 21st. Finally, The Goldman Sachs Group increased their target price on Ultragenyx Pharmaceutical from $67.00 to $76.00 and gave the stock a “buy” rating in a report on Friday, August 2nd. Two equities research analysts have rated the stock with a hold rating and twelve have given a buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $86.69.

Ultragenyx Pharmaceutical Stock Performance

Shares of NASDAQ:RARE opened at $50.43 on Thursday. The company’s fifty day moving average is $55.19 and its 200-day moving average is $48.12. Ultragenyx Pharmaceutical has a 52 week low of $34.06 and a 52 week high of $60.37. The company has a market capitalization of $4.65 billion, a PE ratio of -6.91 and a beta of 0.58.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last announced its quarterly earnings results on Tuesday, November 5th. The biopharmaceutical company reported ($1.40) EPS for the quarter, beating the consensus estimate of ($1.45) by $0.05. Ultragenyx Pharmaceutical had a negative return on equity of 266.02% and a negative net margin of 121.57%. The business had revenue of $139.49 million for the quarter, compared to analyst estimates of $135.28 million. During the same quarter in the previous year, the firm earned ($2.23) EPS. Ultragenyx Pharmaceutical’s quarterly revenue was up 42.3% on a year-over-year basis.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the company. Headlands Technologies LLC acquired a new position in Ultragenyx Pharmaceutical in the first quarter valued at about $28,000. nVerses Capital LLC bought a new position in shares of Ultragenyx Pharmaceutical during the 2nd quarter valued at about $33,000. UMB Bank n.a. grew its position in shares of Ultragenyx Pharmaceutical by 58.1% in the 2nd quarter. UMB Bank n.a. now owns 958 shares of the biopharmaceutical company’s stock valued at $39,000 after purchasing an additional 352 shares during the period. Values First Advisors Inc. bought a new stake in Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $56,000. Finally, Capital Performance Advisors LLP acquired a new stake in Ultragenyx Pharmaceutical during the 3rd quarter worth approximately $107,000. Institutional investors own 97.67% of the company’s stock.

Insider Activity at Ultragenyx Pharmaceutical

In other Ultragenyx Pharmaceutical news, CEO Emil D. Kakkis sold 20,000 shares of the company’s stock in a transaction on Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total transaction of $1,117,000.00. Following the completion of the sale, the chief executive officer now owns 2,223,985 shares in the company, valued at approximately $124,209,562.25. The trade was a 0.00 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other Ultragenyx Pharmaceutical news, CFO Howard Horn sold 7,465 shares of the firm’s stock in a transaction dated Thursday, October 10th. The stock was sold at an average price of $52.76, for a total transaction of $393,853.40. Following the transaction, the chief financial officer now owns 92,301 shares in the company, valued at approximately $4,869,800.76. This trade represents a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Emil D. Kakkis sold 20,000 shares of the company’s stock in a transaction dated Tuesday, September 3rd. The shares were sold at an average price of $55.85, for a total value of $1,117,000.00. Following the completion of the sale, the chief executive officer now directly owns 2,223,985 shares of the company’s stock, valued at approximately $124,209,562.25. This trade represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 27,556 shares of company stock worth $1,515,967 over the last ninety days. Company insiders own 5.80% of the company’s stock.

About Ultragenyx Pharmaceutical

Ultragenyx Pharmaceutical Inc, a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia.